| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Cash | 108,862 | |||
| Prepaid expenses | 6,289 | |||
| Other current assets | 596,186 | |||
| Total current assets | 711,337 | |||
| Right-of-use asset | 75,837 | |||
| Total assets | 787,174 | |||
| Accrued expenses | 575 | |||
| Accounts payable | 269 | |||
| Interest payable | 4,447 | |||
| Lease liability, current | 70,636 | |||
| Total current liabilities | 75,927 | |||
| Lease liability, noncurrent | 5,816 | |||
| Loan from shareholders | 400,000 | |||
| Total liabilities | 481,743 | |||
| Common stock, 475,000,000 shares authorized 0.0001 par value 24,000,000 shares issued and outstanding as of june 30, 2025, and december 31, 2024 | 2,400 | |||
| Preferred stock, 25,000,000 shares authorized 0.0001 par value 1,000,000 shares issued and outstanding as of june 30, 2025, and december 31, 2024 | 100 | |||
| Common stock to be issued | 200,000 | |||
| Additional paid-in capital | 923,309 | |||
| Accumulated deficit | -820,378 | |||
| Total shareholders equity | 305,431 | |||
| Total liabilities and shareholders equity | 787,174 | |||
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)